Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 576-582

  Josefsson, Martin ^a,b   Roman, Markus ^a   Skogh, Elisabeth ^b   Dahl, Marja Liisa ^c,d  

^a Department of Forensic Genetics and Forensic Toxicology   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebrospinal fluid; LC MS MS; N desmetylolanzapine; Olanzapine; Serum; Tandem mass spectrometry

Indexed keywords

DRUG METABOLITE; N DESMETHYLOLANZAPINE; OLANZAPINE; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CALIBRATION; CEREBROSPINAL FLUID ANALYSIS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TANDEM MASS SPECTROMETRY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 77954863398     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.03.040     Document Type: Article

References (23)

1. Beasley C., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996, 124:159-167.
2. Bymaster F., Perry K., Nelson D., Wong D., Rasmussen K., Moore N., Calligaro D. Olanzapine: a basic science update. Br. J. Psychiatry 1999, 174:36-40.
3. Fountoulakis K., Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int. J. Neuropsychopharmacol. 2008, 11:999-1029.
4. Beasley C., Dellva M.A., Tamura R., Morgenstern H., Glazer W., Ferguson K., Tollefson G. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br. J. Psychiatry 1999, 174:23-30.
5. Melkersson K.I., Dahl M.-L. Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs 2004, 64:701-723.
6. Callaghan J.T., Bergstrom R., Ptak L., Beasley C. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 1999, 37:178-193.
7. Skogh E., Reis M., Dahl M.-L., Lundmark J., Bengtsson F. Therapeutic drug monitoring data on olanzapine ant its N-demethyl metabolite in the naturalistic clinical setting. Ther. Drug Monit. 2002, 24:518-526.
8. Nordin C., Almé B., Bondesson U. CSF and serum concentrations of clozapin and its demetyl metabolite: a pilot study. Psychopharmacology 1995, 122:104-107.
9. Wang J.S., Taylor R., Ruan Y., Donovan J.L., Markowitz J.S., Lindsay De Vane C. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 2004, 29:551-557.
10. Zhang G., Terry A.V., Bartlett M.G. Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 2007, 856:20-28.
11. Catlow J.T., Barton R.D., Clemens M., Gillespie T.A., Goodwin M., Swanson S.P. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 1995, 668:85-90.
12. Aravagiri M., Ames D., Wirshing W.C., Marder S.R. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther. Drug Monit. 1997, 19:307-313.
13. Raggi M.A., Casamenti G., Mandrioli R., Volterra V. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. J. Chromatogr. B 2001, 750:137-146.
14. Zhou Z., Li X., Li K., Xie Z., Cheng Z., Peng W., Wang F., Zhu R., Li H. Simultaneous determination of clozapine, olanzapin, risperidon and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B 2004, 802:257-262.
15. Chin C., Zhanz Z.P., Karnes H.T. A study on matrix effect on an LC/MS/MS assay for olanzapine and desmethyl olanzapine. J. Pharm. Biomed. Anal. 2004, 35:1149-1167.
16. Nirogi R.V.S., Kandikere V.N., Shukla M., Mudigonda K., Maurya S., Boosi R., Yerramilli A. Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. J. Pharm. Biomed. Anal. 2006, 41:935-942.
17. Zhang G., Terry A.V., Bartlett M.G. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol, and ziprasidone in rat plasma. Rapid Commun. Mass Spectrom. 2007, 21:920-928.
18. Choonga E., Rudazb S., et al. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J. Pharm. Biomed. Anal. 2009, 50:1000-1008.
19. Josefsson M., Kronstrand R., Andersson J., Roman M. Evaluation of electrospray ionisation liquid chromatography-tandem mass spectrometry for rational determination of a number of neuroleptics and their metabolites in human body fluids and tissues. J. Chromatogr. B 2003, 789:151-157.
20. Zhang G., Terry A.V., Bartlett M.G. Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol, and ziprasidone in rat brain tissue. J. Chromatogr. B 2007, 858:276-281.
21. Klose Nielsen M.K., Stybe Johansen S. Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2009, 33:212-217.
22. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
23. E. Skogh, I. Sjödin, M. Josefsson, M.-L. Dahl, Olanzapine and its N-desmethyl metabolite in serum and cerebrospinal fluid in patients with schizophrenia or schizoaffective disorder-influence of gender, age, smoking and pharmacogenetics, J. Clin. Psychopharmacol., submitted for publication.